Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to twelve newly hired non-executive employees effective May 4, 2026 under its 2019 Inducement Stock Incentive Plan pursuant to Nasdaq Rule 5635(c)(4).

The awards include non-statutory stock options to purchase an aggregate of 127,650 shares and restricted stock units totaling 41,550 shares; option exercise price is $9.71 per share, equal to the closing market price on the grant date. Options have a ten-year term and vest over four years; RSUs vest in three equal annual installments.

AI-generated analysis. Not financial advice.

Positive

• 127,650 stock options granted as inducements
• 41,550 restricted stock units representing potential common shares
• Exercise price $9.71 per share, equal to closing market price on grant date
• Vesting schedules align new hires with multi-year service (options 4 years, RSUs 3 years)

Negative

• 169,200 shares potentially issuable could increase share count and cause dilution
• Options 10-year term extends potential overhang for a decade

Key Figures

Inducement stock options: 127,650 shares Inducement RSUs: 41,550 shares Option exercise price: $9.71 per share +3 more

6 metrics

Inducement stock options 127,650 shares Non-statutory stock options under 2019 Inducement Stock Incentive Plan

Inducement RSUs 41,550 shares Restricted stock unit awards for new non-executive employees

Option exercise price $9.71 per share Equal to OCUL Nasdaq closing price on May 4, 2026

Option term 10 years Non-statutory stock option grant duration

Option vesting 4 years 25% at 1 year, then monthly over next 3 years

RSU vesting 3 years Equal annual installments over three years

Market Reality Check

Price: $9.65 Vol: Volume 2,081,987 is below...

normal vol

$9.65 Last Close

Volume Volume 2,081,987 is below the 20-day average of 2,917,230 (relative volume 0.71x). normal

Technical Shares at $9.68 are trading below the 200-day MA at $11.01 and 41.12% under the 52-week high.

Peers on Argus

OCUL was down 0.31% pre-news with mixed peer moves: BEAM (-0.61%), LQDA (-0.63%)...

OCUL was down 0.31% pre-news with mixed peer moves: BEAM (-0.61%), LQDA (-0.63%), TVTX (-6.26%) declined while TARS (+2.01%) and BLTE (+0.16%) rose, suggesting stock-specific trading rather than a coordinated sector move.

Historical Context

5 past events · Latest: May 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 05	Earnings and pipeline	Positive	-0.6%	Q1 2026 results with positive Phase 3 SOL-1 data and strong cash runway.
Apr 29	Clinical trial update	Positive	-1.2%	First patient enrolled in SOL-X long-term extension trial for AXPAXLI in wet AMD.
Apr 28	Earnings date notice	Neutral	-2.1%	Announcement of date and time for Q1 2026 earnings call and webcast.
Apr 27	Conference participation	Positive	+0.3%	Planned May scientific and investor conference presentations and webcasts.
Apr 22	Investor event	Positive	+3.5%	Announcement of June 17, 2026 Investor Day with leadership and key opinion leaders.

Pattern Detected

Recent OCUL news has often seen shares trade lower or only modestly higher even on seemingly positive clinical and corporate updates.

Recent Company History

Over the last several weeks, Ocular Therapeutix released multiple updates tied to AXPAXLI and corporate events. On Apr 22, an Investor Day announcement saw shares gain 3.54%, while conference participation news on Apr 27 coincided with a modest 0.32% rise. However, clinical and trial-enrollment updates on Apr 28–29 and Q1 2026 earnings on May 5 were followed by declines between 0.61% and 2.10%. Today’s inducement grants fit into a period of active hiring, clinical expansion, and frequent investor communications.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-30

OCUL has an effective Form S-3ASR shelf registration dated Sep 30, 2025, allowing it to offer various securities, including debt and equity, via future prospectus supplements. The shelf has been used at least once (a 424B5 filing on Sep 30, 2025) and remains effective through Sep 30, 2028, supporting general corporate and R&D funding needs.

Market Pulse Summary

This announcement details standard Nasdaq Rule 5635(c)(4) inducement grants tied to recent hiring, i...

Analysis

This announcement details standard Nasdaq Rule 5635(c)(4) inducement grants tied to recent hiring, including 127,650 non-statutory options and 41,550 RSUs at an exercise price of $9.71. The awards sit alongside an already active clinical and corporate calendar highlighted by recent Phase 3 progress and an upcoming Investor Day. Investors following OCUL may track how such equity incentives support talent retention while also considering existing capital structure tools such as the effective S-3ASR shelf.

Key Terms

nasdaq listing rule 5635(c)(4), 2019 inducement stock incentive plan, non-statutory stock option, restricted stock unit, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"inducement grants under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

2019 inducement stock incentive plan financial

"under Ocular’s 2019 Inducement Stock Incentive Plan in accordance"

A 2019 inducement stock incentive plan is a company-created program, often named for the year it was adopted, that grants stock-based awards—such as options or restricted shares—to new hires as a recruiting incentive and is typically established outside the main shareholder-approved equity plan. Investors pay attention because these awards act like signing bonuses paid in company stock: they can reduce existing owners' percentage of the company, align new employees’ interests with shareholders, and signal how urgently the company is hiring top talent.

non-statutory stock option financial

"consist of non-statutory stock option awards to purchase up"

A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.

restricted stock unit financial

"and restricted stock unit awards representing the right to receive"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

exercise price financial

"The stock option awards have an exercise price of $9.71 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to twelve newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of May 4, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 127,650 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 41,550 shares of Ocular’s common stock. The stock option awards have an exercise price of $9.71 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

What inducement awards did Ocular Therapeutix (OCUL) grant on May 4, 2026?

The company granted non-statutory stock options for 127,650 shares and RSUs for 41,550 shares. According to the company, these awards were made as inducements to twelve newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan.

What is the exercise price and term of the OCUL stock options granted May 4, 2026?

The stock option exercise price is $9.71 per share and each option has a ten-year term. According to the company, $9.71 equals the closing price on the grant date and options vest over four years subject to continued service.

How do the OCUL option and RSU vesting schedules work for the May 2026 inducement grants?

Options vest over four years with 25% after one year and monthly thereafter; RSUs vest in three equal annual installments. According to the company, both award types vest subject to the recipient’s continued service through applicable vesting dates.

How many employees received inducement awards in Ocular Therapeutix's May 2026 grants?

Twelve newly hired non-executive employees received inducement awards. According to the company, the grants were made as material inducements to each recipient’s acceptance of employment under Nasdaq Listing Rule 5635(c)(4).

What is the total number of shares potentially issuable from OCUL's May 4, 2026 inducement grants?

The awards could result in up to 169,200 shares issuable in aggregate (options plus RSUs). According to the company, this total combines 127,650 option shares and 41,550 restricted stock units granted to new hires.